Cyclo Therapeutics Inc - Class A

CYTH | $1.24 -1.59% -1.61% 250

(0.0% 1d) (-22.5% 1m) (76.6% 1y) (0.0% 2d) (0.0% 3d) (-10.8% 7d) (-57.14% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 35,607,518
https://www.cyclotherapeutics.com
Sec Filling | Patents | 8 employees

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

cholesterol genetic alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Panbela Therapeutics Inc

PBLA | $0.54 -8.48% -6.31% 0

Professional, Scientific, and T...

(0.0% 1d) (-15.6% 1m) (-96.7% 1y) (0.0% 2d) (0.0% 3d) (5.9% 7d) (-45.02% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 2,621,625
http://www.sunbiopharma.com/
Sec Filling | Patents | 6 employees

(US) Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. isdedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents and in treating other types of cancer.

cancer treatment pancreatic

add to watch list Paper trade email alert is off

Seer Inc - Class A

SEER | $1.79 -2.72% -2.22% 10

Professional, Scientific, and T...

(0.0% 1d) (-5.3% 1m) (-56.0% 1y) (0.0% 2d) (0.0% 3d) (1.7% 7d) (-31.92% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 108,703,498
https://seer.bio
Sec Filling | Patents | 60 employees

Seek Inc. is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. The Company's Proteograph is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. The Company's designed the Proteograph to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution broadly available to life sciences researchers.

housing

add to watch list Paper trade email alert is off

ImmunoPrecise Antibodies Ltd

IPA | $1.24 -8.82% -11.48% 110K

Professional, Scientific, and T...

(0.0% 1d) (-11.4% 1m) (-51.9% 1y) (0.0% 2d) (0.0% 3d) (-10.8% 7d) (-9.73% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 32,630,922
http://www.immunoprecise.com/
Sec Filling | Patents | 2021 employees

(CA) IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company's therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes.

covid antibody

add to watch list Paper trade email alert is off